We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genome-Wide Analysis Pinpoints Cancer Cell Genes Linked to Metastasis and Chemotherapy Susceptibility

By LabMedica International staff writers
Posted on 02 May 2013
Cancer researchers used genome-wide analyses to investigate the link between gene expression and anticancer compound sensitivity and cancer cell invasion.

Investigators at Academia Sinica (Taipei, Taiwan, Republic of China) and the National Taiwan University College of Medicine (Taipei, Republic of China) utilized the [US] National Cancer Institute's (Bethesda, MD, USA) panel of 60 tumor cell lines to gain insights on the genetic mechanism of drug sensitivity and on the contributing molecular factors to invasion heterogeneity. More...
The NCI-60 human tumor cell line anticancer drug screen was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumors in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumor-cell kill.

In the current study, the investigators identified invasion-associated (IA) genes by correlating their invasion profiling data with the Affymetrix gene expression data on NCI-60. They then employed the recently released chemosensitivity data of 99 anticancer drugs of known mechanism to investigate the gene-drug correlation, focusing on the IA genes. Afterwards, they collected data from four independent drug-testing experiments to validate the findings on compound response prediction. Finally, they obtained published clinical and molecular data from two recent adjuvant chemotherapy cohorts, one on lung cancer and one on breast cancer, to test the performance of their gene signature for patient outcome prediction.

Results published in the April 16, 2013, online edition of the journal BMC Medicine identified 633 IA genes from the invasion-gene expression correlation study. For each of the 99 drugs, the investigators obtained a subset of IA genes whose expression levels correlated with drug-sensitivity profiles. They identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32, and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib. This eight-gene signature for chemosensitivity prediction was validated by a total of 107 independent drug tests on 78 tumor cell lines, most of which were outside of the NCI-60 panel.

The eight-gene signature predicted relapse-free survival for the lung and breast cancer patients and featured the cancer hallmark epidermal growth factor receptor (EGFR) and genes involved in cell adhesion, migration, invasion, tumor growth, and progression.

Senior author Dr. Ker-Chau Li, professor of statistical science at Academia Sinica, said, "Our study found eight genes which were involved in invasion, and the relative activation of these genes correlated to chemotherapy outcome, including the receptor for growth factor EGF. We also found that some invasion genes had unique patterns of expression that reflect the differential cell responses to each of the chemotherapy agents - five drugs (paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib) had the greatest effect."

Contributing author Dr. Pan-Chyr Yang, professor of medicine at National Taiwan University, said, "The discovery of prognostic biomarkers for chemotherapy patients remains critical toward improving the efficacy of cancer treatment. The eight-gene signature obtained here may help choice of treatment as part of individualized cancer therapy and our method of gene discovery may be applicable in studying other cancers."

Related Links:

Academia Sinica
National Taiwan University College of Medicine
National Cancer Institute




New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.